Kazia Therapeutics (KZIA) trims at-the-market offering program to $80M
Rhea-AI Filing Summary
Kazia Therapeutics Limited (KZIA) has reduced the capacity of its at-the-market issuance program for American Depositary Shares. A prospectus supplement filed on August 28, 2026 amends the existing Sales Agreement with Leerink Partners LLC, lowering the maximum aggregate offering price of ADSs that may be offered, issued and sold under the program from $100,000,000 to $80,000,000. This supplement relates to the company’s effective shelf registration statement on Form F-3 (File No. 333-294392).
Positive
- None.
Negative
- None.
Key Figures
Revised ATM maximum aggregate offering price: $80,000,000
Previous ATM maximum aggregate offering price: $100,000,000
Registration statement file number: 333-294392
3 metrics
Revised ATM maximum aggregate offering price
$80,000,000
Maximum aggregate offering price of ADSs that may be offered, issued and sold under the Sales Agreement after the prospectus supplement
Previous ATM maximum aggregate offering price
$100,000,000
Maximum aggregate offering price of ADSs that could be offered, issued and sold under the Sales Agreement before the prospectus supplement
Registration statement file number
333-294392
Form F-3 registration statement supplemented by the August 28, 2026 prospectus supplement
Key Terms
prospectus supplement, Rule 424(b)(5), Form F-3, American Depositary Shares, +1 more
5 terms
prospectus supplement regulatory
"filed a prospectus supplement (the “Prospectus Supplement”) pursuant to Rule 424(b)(5)"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Rule 424(b)(5) regulatory
"filed a prospectus supplement (the “Prospectus Supplement”) pursuant to Rule 424(b)(5)"
Form F-3 regulatory
"supplements the Company’s registration statement on Form F-3 (File No. 333-294392)"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
Sales Agreement financial
"under the Sales Agreement, dated March 17, 2026 (the “Sales Agreement”)"
A sales agreement is a written contract that sets out the terms for selling goods, services, or assets, specifying price, delivery, payment schedule and responsibilities of each side. For investors it matters because it creates a predictable stream of revenue or cash obligations, clarifies timing and risk, and can change a company’s value or forecasts much like a signed order turns a customer’s verbal intent into a firm commitment.
Offering Details
ATM
Offering
Offering Type
ATM
FAQ
What change did KZIA make to its at-the-market offering capacity?
Kazia Therapeutics Limited reduced the maximum aggregate offering price of American Depositary Shares that may be offered, issued and sold under its Sales Agreement with Leerink Partners LLC from $100,000,000 to $80,000,000, as reflected in a prospectus supplement filed on August 28, 2026.
Which registration statement does the new Kazia (KZIA) prospectus supplement relate to?
The prospectus supplement filed by Kazia Therapeutics Limited on August 28, 2026 supplements its shelf registration statement on Form F-3, File No. 333-294392, which was initially filed with the U.S. Securities and Exchange Commission on March 18, 2026.
What security is covered by Kazia’s (KZIA) amended Sales Agreement?
The amended Sales Agreement between Kazia Therapeutics Limited and Leerink Partners LLC covers the at-the-market offering of the company’s American Depositary Shares (ADSs), with a revised maximum aggregate offering price of $80,000,000 under the prospectus supplement.
Who is Kazia Therapeutics’ (KZIA) sales agent under the at-the-market program?
Under the Sales Agreement dated March 17, 2026, Leerink Partners LLC acts as the sales agent for Kazia Therapeutics Limited’s at-the-market offering of American Depositary Shares, now capped at a $80,000,000 maximum aggregate offering price.
When did Kazia Therapeutics (KZIA) file the prospectus supplement reducing its ATM size?
Kazia Therapeutics Limited filed the relevant prospectus supplement with the U.S. Securities and Exchange Commission on August 28, 2026, reducing the maximum aggregate offering price of ADSs under the Sales Agreement from $100,000,000 to $80,000,000.
AI-generated analysis. How Rhea-AI works. Not financial advice.
